Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Antiviral Therapy|November 1, 2012
Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the USKate Buchacz, Rose K Baker, Frank J Palella, et al.
British Journal of Pharmacology|June 7, 2017
Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaineLinda D Simmler, Allison M J Anacker, Michael H Levin, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
Human Molecular Genetics|January 7, 2020
Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiencyMuhammad Ansar, Emmanuelle Ranza, Madhur Shetty, et al.
The Journal of Infectious Diseases|August 26, 2016
Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010Kate Buchacz, Bryan Lau, Yuezhou Jing, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Frontiers in Immunology|April 18, 2024
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognitionAnnie Borch, Ibel Carri, Birkir Reynisson, et al.
JAMA Ophthalmology|December 4, 2025
Early-Onset Retinopathy in Patients With Variants in SLC6A6 Leading to Impaired Taurine TransportMukhtar Ullah, Atta Ur Rehman, Madhur Shetty, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Pageof 13